Tetracosactide - Novartis

Drug Profile

Tetracosactide - Novartis

Alternative Names: Corticotropin tetracosapeptide; Cosyntropin injection; Cosyntropin zinc hydroxide injection; MNK-1411; Synacthen; Synacthen Depot; Tetracosactide hexa-acetate salt - Novartis

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Alliance Pharmaceuticals Limited; Defiante Farmaceutica; Leadiant Biosciences; Mallinckrodt plc; Novartis; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Corticosteroids; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adrenal insufficiency; Autoimmune disorders; Infantile spasms; Inflammation; Multiple sclerosis
  • Phase I Duchenne muscular dystrophy

Most Recent Events

  • 14 Jul 2017 Tetracosactide licensed to West Therapeutic Development in USA for the treatment of Infantile spasms and Nephrotic syndrome
  • 12 Jul 2017 Tetracosactide receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 12 Jul 2017 Mallinckrodt plans a phase II trial for Duchenne muscular dystrophy in late 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top